Compare CLNN & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLNN | QTTB |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 44.3M |
| IPO Year | N/A | 2018 |
| Metric | CLNN | QTTB |
|---|---|---|
| Price | $5.52 | $6.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $32.67 | $14.00 |
| AVG Volume (30 Days) | 57.7K | ★ 160.7K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $82.05 | N/A |
| P/E Ratio | ★ N/A | $2.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.28 | $1.38 |
| 52 Week High | $13.50 | $6.37 |
| Indicator | CLNN | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 58.80 | 79.58 |
| Support Level | $3.43 | $1.64 |
| Resistance Level | $5.71 | N/A |
| Average True Range (ATR) | 0.43 | 0.51 |
| MACD | 0.10 | 0.17 |
| Stochastic Oscillator | 92.50 | 94.50 |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.